CClinicalTrials.gg
CompletedNCT04005534Updated Apr 16, 2024

US-Guided Preemptive Brachial Plexus Blockade May Reduce Post-operative Pain: a Randomized Study

An interventional study of Standard group and Preemptive group in Postoperative Pain and Rotator Cuff Injuries, sponsored by University of Sao Paulo General Hospital. Completed at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Sex
All
01

Study summary

Intense e recurrent nociceptive stimulation, which occurs in the postoperatively, can trigger sensitization of the peripheral and central nociceptive pathway, leading to chronic pain. Patients with rotator cuff injury often present to surgery due to referred moderate to intense long-term pain. During the immediate postoperative period, pain is rare due to the routine administration of a brachial plexus blockade as an adjuvant to improve the quality of postoperative analgesia. However, after the second postoperative day, the effect of the blockade ceases, and the pain becomes high and hard to treat, leading the patient to request administration of more frequent and more potent analgesics. The aim of this project is to assess the postoperative analgesic benefits of a brachial plexus blockcade 2 days before arthroscopic surgical correction of rotator cuff injury by reducing the sensitization of the nociceptive pathway.

Read the detailed description

This is a prospective, controlled, blinded, randomized trial design, based on the PICO structured question: "Brachial plexus block 48 h before arthroscopic surgery for correction of rotator cuff tear in a patient with chronic shoulder pain can influence the postoperative pain? The project will be submitted to the Research Ethics Committee and, after its approval, will be submitted to the Ethics Committee of the institution where the research will be carried out. After approval at these instances and registration at clinicaltrials.gov, a sample of 70 individuals will be selected from a population of patients scheduled for arthroscopic correction of rotator cuff tears. Study subjects will be randomly distributed by electronic draw into two groups: the standard group (SG) and the preemptive group (PG). All patients in both groups will be instructed on the visual analogue (AVS) and numeric pain scales (NPS). The groups will be drawn by a member of the team who will only have the function of controlling the flow of the groups, without participating in any evaluation regarding the trial protocol. All patients in the study will be submitted to BPB and sedation immediately before the surgery. GP patients will undergo BPB 48 h before surgery to try to desensitize the nociceptive pathway. Individuals in the stardard group (SG) will be submitted to an ultrasonographic examination of the topography of the shoulder to be operated on, without knowing whether any therapeutic procedure was performed or just an examination. Both components of both groups will be instructed to use a sling after the procedure 48 h before surgery (BPB or US exam).

INCLUSION CRITERIA: patients scheduled for arthroscopic correction of rotator cuff injury, body mass index \< 35 kg/m², shoulder pain complaint for at least 3 months and intensity ≥ 4 (0 to 10) on the day of the pre-anesthetic consultation , ASA I or II, mental and legal capacity to spontaneously accept and sign the informed consent form.

EXCLUSION CRITERIA: allergy to any drug in the study protocol, refusal to participate, contraindication to any substance or technique described in the protocol, intellectual or other limitations that make it difficult to understand the questions and guidelines related to the project protocol, intercurrence at the time of the BPB, not properly installing the BPB (assessment of its sensory effect).

SAMPLE SIZE. The authors carried out an unpublished study comparing two groups of 30 patients for arthroscopic correction of cuff injuries under BPB guided by a peripheral nerve stimulator associated with general anesthesia. One group received BPB 2 days before surgery to assess the possible advantage of reducing the sensitization of chronically stimulated nociceptive pathways in reducing postoperative pain. It is known that postoperative pain in this scenario becomes more intense from the third day on. In this study, pain on the third postoperative night had a mean score of 3.68 (END - 0 to 10), with a standard deviation of 3.04. Our goal is to reduce scores below 3 on the third postoperative night (we will consider an average of 2). Using Pocock's formula12, for a significance level of 95% and a statistical power of 80%, the calculated sample size was 25.86. We increased it to 35 to compensate for losses, with a total of 70 patients in the study.

TECHNIQUE. After guidance on the protocol and signature of the TCLE (Annex 1), the 70 individuals from the study sample will be randomly distributed into two groups (preemptive group - PG; standard group - SG) using an electronic draw offered on the website www.random.org. After distributing the numbers, the same professional responsible for it will number 70 brown envelopes from 1 to 70 and inside each one of them will put the name of the group that corresponds to it, according to the order established by the draw. The order of arrival of patients at the pre-anesthetic evaluation office will correspond to the order in which the envelopes are numbered. The professional responsible for drawing lots and distributing envelopes will not participate in anesthesia or evaluations and will keep the draw secret for security and any clarifications. In the pre-anesthetic consultation, patients with shoulder pain for more than 3 months and with a pain score on the day of the consultation ≥ 4 who agreed to participate in the study will respond to the brief pain inventory validated for Brazilian Portuguese13, to the short version of the questionnaire McGill's pain test14 and the quality of life questionnaire validated for Brazilian Portuguese (WHOQOL-SRPB)15.

After basic monitoring (electrocardioscopy - ECG, oximetry and non-invasive blood pressure - NIBP) and obtaining venous access, PG patients will receive BPB 48 h before surgery. The BPBs in the study will be US-guided. In preemptive BPB (PG), 15 ml of 1% ropivacaine will be injected. Patients in the SG will be submitted to an ultrasound examination of the brachial plexus, and even if they are not submitted to a puncture or invasive process, they will not know which group they will participate in to keep them covered. The anesthesiologist who performs the previous BPB may be the same one who will perform the BPB for that patient on the day of the surgery, since the mark of the first BPB will hardly have disappeared, making it practically impossible to cover up this sign. Likewise, the anesthesiologist who will perform the previous ultrasound examination may be the same one who will perform the BPB on the day of the surgery. All patients in both groups will be instructed to use a sling on the shoulder to be operated after the previous BPB or previous ultrasound examination, in an attempt to keep the group covered. The anesthesiologist conducting the sedation and assessment of patients will not be able to participate in the blocks or examination of the patient who will be administering the sedation or performing the assessment. Patients will be instructed to use dipyrone 1 g every 6 hours and paracetamol (500 mg) associated with codeine (30 mg) in case of pain ≥ 4 in the two days prior to surgery. On the day of surgery, all patients will be asked about the intensity of pain at that time (record). After that, patients in both groups will undergo basic monitoring (as mentioned above) upon entering the operating room, obtaining venous access, sedation with 3 mg of midazolam and fentanyl 50 µg, and BPB with the same technique and block material preemptive. After confirming the installation of the BPB, the patient will receive intravenous ketamine 15 mg. The adjuvant medication will be dipyrone 30 mg/kg, cephalozine 2 g, ketoprofen 100 mg, ondansetron 8 mg, dexamethasone 4 mg. Hemodynamic changes will be managed at the discretion of the providing anesthetist.

It is routine for the team to perform surgeries in the morning and to discharge patients in the late afternoon, except for exceptions due to intercurrences. In the postoperative period, all patients will receive dipyrone 1 g every 6 hours and the combination of paracetamol (500 mg) and codeine (30 mg) as rescue for postoperative pain ≥ 4.

All patients will receive telephone contact from the evaluator between 5:00 pm and 7:00 pm of the first three postoperative days, when they will respond when the first pain ≥ 4 occurred in the postoperative period, what is the consumption of paracetamol/codeine. In the first two days, the level of pain at the time of the interview and the average pain during the day will be recorded. On the third day, patients will answer the brief pain inventory questionnaire13, the McGill pain questionnaire14 and the quality of life questionnaire (WHOQOL)15

02

Conditions studied

  • Postoperative Pain
  • Rotator Cuff Injuries

Keywords

  • Postoperative pain
  • Rotator cuff injuries
  • Preemptive analgesia
03

In context

Pain, Postoperative

5,089 studies on the registry are indexed under Pain, Postoperative; 1,137 are open to participants now.

This study's enrollment of 70 is close to the median of 75 across 4,341 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

University of Sao Paulo General Hospital is the lead sponsor of 595 studies on the registry; 98 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Body mass index \< 35 kg/m²
  • shoulder pain lasting > 3 months
  • pain score > 3 (visual analog scale and verbal response 0 to 10) on the day of pre anesthetic evaluation
  • American Society of Anesthesiologists score I or II
  • mentally and legally capable to understand and consent to study participation.

Exclusion criteria

Exclusion Criteria:

  • Allergy to any medication of the trial
  • refusal to participate, contraindication to any medication or technique described in the protocol of the trial
  • complications from, or failure of brachial plexus blockade.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Placebo comparator
    Standard group

    Patients from this group will undergo only ultrasound examination of the brachial plexus, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.

    Drug: Standard group

  • Experimental
    Preemptive group

    Patients from this group will undergo ultrasound-guided brachial plexus blockade, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.

    Drug: Preemptive group

Interventions

  • DrugStandard group

    Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.

    Also known as: Ultrasound examination

  • DrugPreemptive group

    Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.

    Also known as: Ultrasound guided blockade

06

What researchers measure

Primary outcomes

  1. Pain score on third postoperative day

    Pain assessment through verbal numerical scale of pain (from 0 to 10).

    Time frame: Three days

Secondary outcomes

  1. Pain scores before surgery.

    Postoperative pain through verbal numerical scale of pain (from 0 to 10)

    Time frame: Just before surgery

  2. Pain cores on three postoperative days.

    Postoperative pain through verbal numerical scale os pain (from 0 to 10)

    Time frame: Three days.

  3. Opioid consumption

    Opioid consumption (mg codeine) two days before surgery

    Time frame: Two days before surgery

  4. Opioid consumption

    Opioid consumption (mg codeine) during the first three postoperative days

    Time frame: Three days

07

Study locations

1 site
  • Hospital das Clínicas - Faculdade de Medicina da Universidade de Sao Paulo
    São Paulo, 01246-903, Brazil
08

References and documents

Individual participant data

Plan to share: No — The data will only be available for researchers after the end of the data collection and analysis on request.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04005534
Lead sponsor
University of Sao Paulo General Hospital
Responsible party
Joaquim Edson Vieira (Associate professor, University of Sao Paulo General Hospital) — Principal investigator
First posted
Jul 2, 2019
Start date
Dec 14, 2022
Primary completion
Mar 1, 2024
Completion
Mar 10, 2024
Last update
Apr 16, 2024

Study contacts

Joaquim Vieira, Professor
principal investigator · University of Sao Paulo School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion